§ 01 Overview
Overview
Pfizer oral GLP-1R agonist. Program discontinued April 2025 after a case of drug-induced liver injury despite meeting PK targets.
Phase 2 completed. Program discontinued 14 April 2025 (Pfizer press release).
§ 02 Mechanism
Mechanism of action
Danuglipron was a non-peptide GLP-1R agonist formulated for twice-daily oral dosing. Pfizer ended development following a DILI event in an extension study.
- 01Historical: meaningful oral weight loss in Phase 2
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- Historical trial doses
- Route
- Oral
- Frequency
- Twice daily
§ 04 Evidence
Evidence & research
Phase 2 completed. Program discontinued 14 April 2025 (Pfizer press release).
FDA Status
Not FDA-approved. Development discontinued.
§ 06 News
In the news
2 articles from the last 12 months · updates hourly
JP Morgan 2026 Preview: What Path Will Pfizer Take? - Pharmaceutical Executive
JP Morgan 2026 Preview: What Path Will Pfizer Take? Pharmaceutical Executive
Pfizer's embattled obesity program loses another GLP-1 over poor data and strong competition - Fierce Biotech
Pfizer's embattled obesity program loses another GLP-1 over poor data and strong competition Fierce Biotech
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Transaminase elevation
- 02Nausea
Contraindications
None specified.
§ 10 Questions
Danuglipron FAQ
- What is Danuglipron?
- Pfizer oral GLP-1R agonist. Program discontinued April 2025 after a case of drug-induced liver injury despite meeting PK targets. Danuglipron was a non-peptide GLP-1R agonist formulated for twice-daily oral dosing. Pfizer ended development following a DILI event in an extension study.
- What is Danuglipron used for?
- Reported uses include historical: meaningful oral weight loss in phase 2. Evidence strength is rated Experimental — see the evidence section for detail.
- How is Danuglipron dosed?
- Commonly referenced dosing is Historical trial doses, typically twice daily, administered Oral. This is educational reference only; consult a licensed clinician before use.
- What are the side effects of Danuglipron?
- Commonly reported side effects include transaminase elevation and nausea. This list is not exhaustive.
- Is Danuglipron legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Not FDA-approved. Development discontinued..
§ 11 References
Selected references
- 01
Phase 2 obesity
NCT04707313
- 02
Phase 2b T2D
NCT06567327